Company news

Opus Genetics, Inc. news in 2026

Opus Genetics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference

November 3, 2026

Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

November 2, 2026

Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations

October 29, 2026

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness

October 21, 2026

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

October 16, 2026

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

October 15, 2026

Opus Genetics to Present at the Chardan Annual Healthcare Conference

October 13, 2026

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

September 9, 2026

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

September 2, 2026

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

August 6, 2026

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

August 3, 2026

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

July 9, 2026

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

July 6, 2026

Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes

June 29, 2026

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

June 26, 2026

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

June 2, 2026

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2026

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

May 27, 2026

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

May 13, 2026

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

May 7, 2026

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

May 4, 2026

Opus Genetics to Participate in Leading Medical Conferences in May 2026

April 27, 2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

April 10, 2026

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

April 5, 2026

Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

March 24, 2026

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

March 9, 2026

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

March 3, 2026

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

February 27, 2026

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

February 24, 2026

Opus Genetics Announces $25 Million Private Placement

February 13, 2026

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

February 2, 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

January 27, 2026

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

January 8, 2026

Decks in 2026